DE69233117D1 - In sich geschlossende "sens-" und "antisense"-oligonukleotide und deren verwendungen - Google Patents

In sich geschlossende "sens-" und "antisense"-oligonukleotide und deren verwendungen

Info

Publication number
DE69233117D1
DE69233117D1 DE69233117T DE69233117T DE69233117D1 DE 69233117 D1 DE69233117 D1 DE 69233117D1 DE 69233117 T DE69233117 T DE 69233117T DE 69233117 T DE69233117 T DE 69233117T DE 69233117 D1 DE69233117 D1 DE 69233117D1
Authority
DE
Germany
Prior art keywords
oligonucleotids
sens
antisense
closed
transcription factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69233117T
Other languages
English (en)
Other versions
DE69233117T2 (de
Inventor
Marta Blumenfeld
Pascal Brandys
Auriol Luc D
Marc Vasseur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Biodevelopment SAS
Original Assignee
Serono Genetics Institute SA
Genset SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Genetics Institute SA, Genset SA filed Critical Serono Genetics Institute SA
Application granted granted Critical
Publication of DE69233117D1 publication Critical patent/DE69233117D1/de
Publication of DE69233117T2 publication Critical patent/DE69233117T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69233117T 1991-04-25 1992-04-24 In sich geschlossende "sens-" und "antisense"-oligonukleotide und deren verwendungen Expired - Fee Related DE69233117T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9105114A FR2675803B1 (fr) 1991-04-25 1991-04-25 Oligonucleotides fermes, antisens et sens et leurs applications.
FR9105114 1991-04-25
PCT/FR1992/000370 WO1992019732A1 (fr) 1991-04-25 1992-04-24 Oligonucleotides fermes, antisens et sens, et leurs applications

Publications (2)

Publication Number Publication Date
DE69233117D1 true DE69233117D1 (de) 2003-08-07
DE69233117T2 DE69233117T2 (de) 2004-04-15

Family

ID=9412249

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69233117T Expired - Fee Related DE69233117T2 (de) 1991-04-25 1992-04-24 In sich geschlossende "sens-" und "antisense"-oligonukleotide und deren verwendungen

Country Status (11)

Country Link
US (1) US6369038B1 (de)
EP (2) EP0581848B1 (de)
JP (1) JPH06506834A (de)
AT (1) ATE244303T1 (de)
AU (1) AU660679B2 (de)
CA (1) CA2102229A1 (de)
DE (1) DE69233117T2 (de)
DK (1) DK0581848T3 (de)
ES (1) ES2199936T3 (de)
FR (1) FR2675803B1 (de)
WO (1) WO1992019732A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119608B2 (en) 1999-01-30 2012-02-21 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a given gene

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683874A (en) * 1991-03-27 1997-11-04 Research Corporation Technologies, Inc. Single-stranded circular oligonucleotides capable of forming a triplex with a target sequence
CA2106386A1 (en) * 1991-04-18 1992-10-19 Barbara C. F. Chu Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences
FR2675803B1 (fr) * 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
US5698391A (en) * 1991-08-23 1997-12-16 Isis Pharmaceuticals, Inc. Methods for synthetic unrandomization of oligomer fragments
JPH07502898A (ja) * 1992-01-13 1995-03-30 デューク・ユニバーシティー 酵素ｒｎａ分子
US6521601B1 (en) * 1992-04-14 2003-02-18 Signal Pharmaceuticals, Inc. Method and composition for inhibition of viral replication
GB2273932A (en) * 1992-11-24 1994-07-06 Stiefel Laboratories Stable oligonucleotides
FR2703053B1 (fr) * 1993-03-26 1995-06-16 Genset Sa Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications .
FR2707880B1 (fr) * 1993-06-30 1995-10-06 Rhone Poulenc Rorer Sa Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodégénératives.
FR2708270B1 (fr) * 1993-07-28 1995-10-20 Genset Sa Oligonucléotides antisens dirigés contre les virus Herpès Simplex de types 1 & 2.
US5859226A (en) * 1993-07-29 1999-01-12 Regents Of The University Of California, The Polynucleotide decoys that inhibit MHC-II expression and uses thereof
CA2168245A1 (en) 1993-07-29 1995-02-09 C. Anthony Hunt Polynucleotide decoys that inhibit mhc-ii expression and uses thereof
US8431119B2 (en) 1993-10-04 2013-04-30 Aventis Pharma S.A. Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases
FR2710846B1 (fr) * 1993-10-04 1995-12-22 Rhone Poulenc Rorer Sa Compositions pharmaceutiques et leur utilisation, notamment dans le traitement des maladies neurogénératives.
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
WO1995017507A1 (en) * 1993-12-23 1995-06-29 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB PLAYS A ROLE
FR2714383B1 (fr) * 1993-12-29 1996-02-09 Centre Nat Rech Scient Contrôle de l'expression de gènes.
AU2116995A (en) * 1994-03-07 1995-09-25 University Of Medicine And Dentistry Of New Jersey Cyclic polycationic polymer-oligonucleotide conjugates and methods for preparing same
US5674683A (en) * 1995-03-21 1997-10-07 Research Corporation Technologies, Inc. Stem-loop and circular oligonucleotides and method of using
FR2732344B1 (fr) 1995-04-03 1997-06-20 Genset Sa Oligonucleotides a liaison covalente transversale, procede de preparation et synthon utile dans le procede
FR2732971B1 (fr) * 1995-04-13 1997-07-04 Genset Sa Oligonucleotide sens inhibiteur de virus herpes simplex (hsv) a structure en haltere
US6509149B2 (en) 1995-06-06 2003-01-21 Hybridon, Inc. HPV-specific oligonucleotides
ES2109177B1 (es) * 1995-10-11 1998-07-16 Univ Barcelona Procedimiento general de preparacion de oligonucleotidos ciclicos e intermedios para el mismo.
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
AU2980297A (en) * 1996-06-10 1998-01-07 Laboratory Of Molecular Biophotonics Photocleavable cyclic oligonucleotide
DE19631919C2 (de) * 1996-08-07 1998-07-16 Deutsches Krebsforsch Anti-Sinn-RNA mit Sekundärstruktur
EP0860167A1 (de) * 1997-01-30 1998-08-26 Robert Gurny DNA und RNA Wirkstoffderivate in Nanopartikeln
AU758004B2 (en) 1997-12-17 2003-03-13 Genset S.A. Extended cDNAs for secreted proteins
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2513336A1 (en) 1998-03-20 1999-09-30 Benitec Australia Ltd. Control of gene expression in a non-human eukaryotic cell, tissue or organ
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
CA2343067A1 (en) * 1998-09-21 2000-03-30 Ribozyme Pharmaceuticals, Inc. Hairpin hybridizer molecules for modulation of gene expression
AU776150B2 (en) * 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
AU2008202208C1 (en) * 1999-01-30 2014-04-24 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a defined gene
CN1375004A (zh) * 1999-04-21 2002-10-16 惠氏公司 抑制多核苷酸序列的功能的方法和组合物
US20040138168A1 (en) * 1999-04-21 2004-07-15 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
DE19935756A1 (de) * 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP1191097A1 (de) * 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induktion von "exon-skipping" in eukaryotischen Zellen
WO2002044321A2 (en) 2000-12-01 2002-06-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rna interference mediating small rna molecules
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
EP1229134A3 (de) * 2001-01-31 2004-01-28 Nucleonics, Inc Verwendung von post-transkriptioneller Genabschaltung zur Identifizierung von Nukleinsäuresequenzen die die Funktion einer Zelle beeinflussen
US7358066B2 (en) 2001-07-24 2008-04-15 Serono Genetics Institute S.A. Variants and exons of the GlyT1 transporter
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
EP1436401A4 (de) * 2001-09-27 2006-06-14 Timothy Albert Holton Stamm-schleife-vektor-system
CN1240439C (zh) * 2002-03-28 2006-02-08 南京凯基生物科技发展有限公司 肿瘤基因开关药物
DK3222724T3 (en) 2002-08-05 2018-12-03 Silence Therapeutics Gmbh ADDITIONALLY UNKNOWN FORMS OF INTERFERRING RNA MOLECULES
WO2004083432A1 (en) 2003-03-21 2004-09-30 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
EP1644531A4 (de) * 2003-06-25 2009-03-11 Somagenics Inc Zur zielunabhängigen zirkularisierung und topologischen verknüpfung fähige polynukleotide
US20050043239A1 (en) * 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) * 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
EP1669450B1 (de) * 2003-09-30 2011-11-09 AnGes MG, Inc. Klammerartiges oligonukleotid und dieses enthaltender arzneistoff
KR100698056B1 (ko) * 2003-12-26 2007-03-23 엘지.필립스 엘시디 주식회사 레이저 빔 패턴 마스크 및 이를 이용한 결정화 방법
AU2005245875C1 (en) 2004-05-13 2017-08-31 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
WO2005117889A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
EP1749096B1 (de) * 2004-05-28 2013-07-17 Mologen AG Herstellungsverfahren geeigneter dna-konstrukte zur spezifischen hemmung der genexpression durch rna-interferenz
CA2584960A1 (en) 2004-10-21 2006-05-04 Charles L. Niblett Methods and materials for conferring resistance to pests and pathogens of plants
CA2598409A1 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
DE202005004135U1 (de) * 2005-03-11 2005-05-19 Klocke Verpackungs-Service Gmbh Mehrkomponentenverpackung mit Applikator
EP1877555A2 (de) * 2005-04-22 2008-01-16 Academisch Ziekenhuis Leiden Modulation der exon-erkennung in prä-mrna durch störung der bindung von sr-proteinen und durch störung der rna-sekundärstruktur
EP1986697B1 (de) * 2006-02-17 2016-06-29 GE Healthcare Dharmacon, Inc. Zusammensetzungen und verfahren zur hemmung einer genverstummung durch rna-interferenz
WO2007123391A1 (en) * 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
EP1857548A1 (de) * 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Mittel und Verfahren zur Induktion von Exon-skipping
ATE524547T1 (de) 2006-08-11 2011-09-15 Prosensa Technologies Bv Einzelsträngige oligonukleotide, welche komplementär zu repetitiven elementen sind, zur behandlung von dns-wiederholungen-instabilitäts- assoziierten erkrankungen
US7943591B2 (en) 2007-05-11 2011-05-17 Adynxx, Inc. Gene expression and pain
CA2693048C (en) * 2007-07-12 2016-10-18 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs or tissues
AU2008273094B2 (en) * 2007-07-12 2013-05-09 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
CA2704049A1 (en) 2007-10-26 2009-04-30 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
JP2011510678A (ja) * 2008-02-08 2011-04-07 プロセンサ ホールディング ビーブイ Ｄｎａ反復不安定性関連遺伝性障害を治療するための方法及び手段
US8628940B2 (en) * 2008-09-24 2014-01-14 Pacific Biosciences Of California, Inc. Intermittent detection during analytical reactions
US8143030B2 (en) 2008-09-24 2012-03-27 Pacific Biosciences Of California, Inc. Intermittent detection during analytical reactions
WO2009120374A2 (en) * 2008-03-28 2009-10-01 Pacific Biosciences Of California, Inc. Methods and compositions for nucleic acid sample preparation
AU2009229157B2 (en) 2008-03-28 2015-01-29 Pacific Biosciences Of California, Inc. Compositions and methods for nucleic acid sequencing
EP2119783A1 (de) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel
US8383369B2 (en) * 2008-09-24 2013-02-26 Pacific Biosciences Of California, Inc. Intermittent detection during analytical reactions
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CN104042618B (zh) 2008-11-13 2018-02-16 吉利德卡利斯托加公司 恶性血液病的治疗
GB0901593D0 (en) 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
WO2010111432A1 (en) 2009-03-24 2010-09-30 Calistoga Pharmaceuticals Inc. Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
US20100257634A1 (en) * 2009-04-03 2010-10-07 Venganza Inc. Bioassay for gene silencing constructs
EA201101507A1 (ru) * 2009-04-20 2012-05-30 Гилеад Калистога Ллс. Способы лечения солидных опухолей
AU2010239779A1 (en) 2009-04-24 2011-11-17 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating DMD
JP2013500257A (ja) 2009-07-21 2013-01-07 ギリアード カリストガ エルエルシー Ｐｉ３ｋインヒビターでの肝障害の処置
AU2010335039B2 (en) 2009-12-24 2015-03-26 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Molecule for treating an inflammatory disorder
GB201013153D0 (en) 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
CN104203289B (zh) 2012-01-27 2020-11-03 比奥马林技术公司 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
WO2013130868A1 (en) * 2012-02-29 2013-09-06 Isis Pharmaceuticals, Inc. Methods for modulating fibrinogen expression
KR20140133590A (ko) 2012-03-05 2014-11-19 길리아드 칼리스토가 엘엘씨 (s)-2-(1-(9h-퓨린-6-일아미노)프로필)-5-플루오로-3-페닐퀴나졸린-4(3h)-온의 다형체 형태
EP2846839B1 (de) 2012-05-10 2019-02-20 Adynxx, Inc. Formulierungen zur abgabe von wirkstoffen
CA2934531C (en) 2013-12-20 2020-02-25 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
US9708327B2 (en) 2013-12-20 2017-07-18 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
MX2016016530A (es) 2014-06-13 2017-03-27 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa.
PT3180434T (pt) 2014-08-15 2019-10-29 Adynxx Inc Chamarizes oligonucleotídicos para o tratamento da dor
CA3104113A1 (en) 2018-06-22 2019-12-26 Asklepios Biopharmaceutical, Inc. Vectors for gene delivery that persist within cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO114469B1 (ro) * 1987-12-15 1999-04-30 Gene Shears Pty Ltd Compus oligoribonucleotidic, procedeu de preparare si metoda de inactivare
US5434070A (en) * 1989-02-24 1995-07-18 The University Of Medicine And Dentistry Of New Jersey Reverse transcriptases from Escherichia coli and Myxococcus xanthus
US5436141A (en) * 1989-02-24 1995-07-25 University Of Medicine And Dentistry Of New Jersey Method for synthesizing stable single-stranded CDNA in eukaryotes by means of a bacterial retron and products
US5405775A (en) * 1989-02-24 1995-04-11 The University Of Medicine And Dentistry Of New Jersey Retrons coding for hybrid DNA/RNA molecules
DE3928900A1 (de) * 1989-08-31 1991-03-07 Europ Lab Molekularbiolog Neue nucleotidderivate, ihre herstellung und ihre verwendung
US5426180A (en) 1991-03-27 1995-06-20 Research Corporation Technologies, Inc. Methods of making single-stranded circular oligonucleotides
AU661490B2 (en) * 1991-03-27 1995-07-27 Research Corporation Technologies, Inc. Single-stranded circular oligonucleotides
CA2106386A1 (en) 1991-04-18 1992-10-19 Barbara C. F. Chu Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences
FR2675803B1 (fr) * 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119608B2 (en) 1999-01-30 2012-02-21 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a given gene
US8202980B2 (en) 1999-01-30 2012-06-19 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a given gene
US9902955B2 (en) 1999-01-30 2018-02-27 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a given gene

Also Published As

Publication number Publication date
EP0572287A3 (de) 1994-01-12
DK0581848T3 (da) 2003-10-27
FR2675803B1 (fr) 1996-09-06
WO1992019732A1 (fr) 1992-11-12
CA2102229A1 (fr) 1992-10-26
EP0581848A1 (de) 1994-02-09
JPH06506834A (ja) 1994-08-04
ES2199936T3 (es) 2004-03-01
EP0572287A2 (de) 1993-12-01
EP0581848B1 (de) 2003-07-02
DE69233117T2 (de) 2004-04-15
AU1759692A (en) 1992-12-21
US6369038B1 (en) 2002-04-09
AU660679B2 (en) 1995-07-06
ATE244303T1 (de) 2003-07-15
FR2675803A1 (fr) 1992-10-30

Similar Documents

Publication Publication Date Title
DE69233117D1 (de) In sich geschlossende "sens-" und "antisense"-oligonukleotide und deren verwendungen
DE69121618D1 (de) Mutierte Luciferase vom Leuchtkäfer, mutiertes Luciferasegen, rekombinante DNS diese Gene enthaltend, und Verfahren zur Herstellung von mutierter Luciferase
MA22905A1 (fr) Nouvelles sequences d'adn .
DE59108644D1 (de) Oligonucleotid-analoge mit terminalen 3'-3'-bzw. 5'-5'-Internucleotidverknüpfungen
DE69627698D1 (de) Eine in kaskaden verlaufende vervielfältigungsreaktion von nukleinsäuren
DK0544894T3 (da) Anvendelse af exo-prøve-nukleotider i genkloning
DE69432586D1 (de) Methode zum generieren von einzelsträngigen dna molekülen
FR2569421B1 (fr) Plasmide et fragment d'adn comprenant un gene pour la resistance a la tetracycline, culture de microorganisme contenant le plasmide precite et microorganisme contenant ledit fragment d'adn
DE69736840D1 (de) Synthese von nukleosiden und polynukleotiden
DE69121975D1 (de) Spezifischer Nachweis von Mycobacterium Tuberculosis
DK0642798T3 (da) Kemisk definerede, ikke polymere valensplatformmolekyler og konjugater deraf
DE69231143D1 (de) Spezifische Nukleotidsequenz enthaltender Masernvirusvakzinstamm und Verfahren zu seiner absoluten Identifizierung
DE59400001D1 (de) Alkenylgruppen aufweisende Siloxancopolymere, deren Herstellung und Verwendung.
NO913814D0 (no) Innskudd av dna med modifiserte transposoner.
ATE390112T1 (de) Verwendung von polysäuren mit enger molmassenverteilung
FR2771753B1 (fr) Gene de chitine-desacetylase, sequence d'adn hybridable, vecteur plasmidique qui le contient et organisme transforme par ce vecteur plasmidique
SE9502259L (sv) Oligonukleotider för att inhibera expression av isoprenylproteintransferas
IL108779A0 (en) Polyribozyme capable of conferring viral resistance to plants, and resistant plants producing said ribozyme
GB0122828D0 (en) Gene expression construct
ATE199397T1 (de) Multiple virus-resistenz aufweisende transgene pflanzen und verfahren zu ihrer herstellung
DE3882900D1 (de) Substituierte veresterte hydroxylamine und deren verwendung als stabilisatoren.
FI964784A (fi) Yhdistelmä-DNA-viruksia, valmistus ja käyttö geeniterapiassa
BR0016347A (pt) Oligonucleotìdios antisenso
DE69534058D1 (de) Genetische sequenzen welche pflanzenkrankheitsresistenz verursachen und verwendungen davon
FI974303A0 (fi) Kontinuerlig maetning av en loesnings specifika vikt och koncentration samt styrning/reglering av aotgaerderna genom slang-/roerstroemning

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: GENSET S.A., EVRY, FR

8339 Ceased/non-payment of the annual fee